📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
10 articles
AVG GRADE
NEUTRAL
score: -0.20
SENTIMENT
BULLISH
TOTAL VIEWS
1
RECENT COVERAGE · 44 ARTICLES
Johnson & Johnson snaps six straight sessions of gains (JNJ:NYSE)
Johnson & Johnson (JNJ) has ended a six-session winning streak, signaling a technical pullback in the healthcare blue-chip after...
Johnson & Johnson (JNJ) Beats Lawsuit Alleging that Talc caused Three Women’s Cancer
Johnson & Johnson (JNJ) secured a favorable legal outcome in talc-related litigation, with the company defeating a lawsuit brought by...
Johnson & Johnson (JNJ) – Among the 10 Best Dividend Stocks to Buy for Passive Income
Johnson & Johnson (JNJ) received a modest price-target increase from Guggenheim Securities, with the analyst lifting its recommendation...
Healthcare stocks have caught fire, sending all 3 of our names to record highs
Healthcare equities are experiencing sustained momentum, with multiple portfolio holdings reaching all-time highs. This breakout...
Why Johnson & Johnson Stock Popped on Friday
Johnson & Johnson (JNJ) experienced a notable intraday rally on Friday, suggesting a shift in market perception despite the stock's...
Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis
Johnson & Johnson presented additional efficacy data for nipocalimab (IMAAVY®) at the European Academy of Neurology congress,...
Lilly, J&J, AbbVie hit all-time highs (LLY:NYSE)
Three large-cap Health Care names—Eli Lilly (LLY), Johnson & Johnson (JNJ), and AbbVie (ABBV)—have reached new 52-week highs, signaling...
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ) represent distinct portfolio positioning within the diversified healthcare space....
Johnson & Johnson (JNJ): Among the Best Stocks For Beginners to Buy Now
Johnson & Johnson (JNJ) received positive coverage as a beginner-friendly equity following the June 11 expansion of TECNIS PureSee IOL...
Johnson & Johnson (JNJ): Among the Best Stocks For Beginners to Buy Now
Johnson & Johnson (JNJ) has been highlighted as an attractive entry point for retail investors seeking established healthcare exposure....
CHMP recommendation advances Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab as a potential standard of care for relapsed/refractory multiple myeloma
Johnson & Johnson's TECVAYLI® combination therapy has secured a positive CHMP recommendation from the European Medicines Agency for...
Johnson & Johnson (JNJ) Dividend Stock Analysis
JNJ dividend analysis articles typically assess the company's capital allocation strategy and yield sustainability for income-focused...
We're trimming a health-care stock into strength and raising our price target
An analyst is executing a tactical trim of JNJ into a period of strength while simultaneously raising price target expectations,...
10 Best Stocks For Beginners to Buy Now
This article presents a curated list of beginner-friendly stocks anchored by commentary from Gary Cohn, who brought executive and policy...
3 Quality Dividend Aristocrats to Buy in June
This article examines dividend aristocrats—companies with 25+ years of consecutive dividend increases—as income-generating alternatives...
Johnson & Johnson: Not Every Dollar Needs To Chase The AI Boom (Upgrade) (NYSE:JNJ)
Johnson & Johnson (JNJ) has been upgraded from Hold to Buy status, reflecting analyst reassessment of the company's strategic...
RQ Bio Announces $115 Million (£85.5 Million) Series A Financing to Advance Long-Acting Antibody Programme RQB01 for Full Season Influenza Prevention
RQ Bio, a private biotech firm, secured $115 million in Series A funding to advance its long-acting antibody program RQB01 targeting...
These 2 stocks are on our radar — here's what it will take for us to buy
The Investing Club's morning meeting identifies two stocks under evaluation for potential portfolio entry. This type of thematic...
US shoulders disproportionate cost of new medications, report finds
A new Office of Health Policy report quantifies a long-standing structural imbalance: U.S. consumers bear approximately 80% of...
1 Vanguard Index Fund Could Turn $450 Per Month Into a $905,200 Portfolio That Pays $16,400 in Annual Dividend Income
This article presents a long-term wealth accumulation scenario using index fund investing with consistent monthly contributions. The...
How Johnson & Johnson (JNJ) Is Using U.S. Manufacturing Investment to Strengthen Its Vision Business
Johnson & Johnson (JNJ) is leveraging U.S. manufacturing capacity expansion as a strategic cornerstone for its vision care division,...
Johnson & Johnson: An Excellent Portfolio Option To Barbell AI, Initiate Buy Rating
Johnson & Johnson (JNJ) is positioned as a defensive equity allocation strategy within a barbell portfolio framework that juxtaposes...
The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026
The Health Care Select Sector SPDR ETF (XLV) faces a pivotal inflection point heading into 2026, with the sector's relative performance...
Notable healthcare headlines for the week: Merck, Moderna, and Biogen in focus
Healthcare equities displayed mixed performance amid divergent fundamental catalysts. Moderna (MRNA) outperformed the XLV health care...
Scanning cancer, up close & personal: A revolution is underway in cancer diagnosis
The article highlights advances in next-generation sequencing (NGS) technology for cancer diagnosis, specifically focusing on its...
This Dividend Portfolio Pays More Than Social Security and a Part-Time Job Combined
This article addresses the strategic use of dividend-paying portfolios as a retirement income tool, comparing yield-based returns to...
Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade
Johnson & Johnson (JNJ) declined 2.48% to $228.39 while the broader market advanced, indicating a divergence between the mega-cap...
Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape
This article surveys the age-related macular degeneration (AMD) clinical trial landscape, highlighting a crowded pipeline of 100+...
3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound
Eli Lilly (LLY), Humana (HUM), and DexCom (DXCM) are emerging as primary drivers of healthcare sector strength, signaling renewed...
CME Outfitters Receives Gold Award at the 2026 Spring Digital Health Awards®
CME Outfitters has received recognition at the 2026 Spring Digital Health Awards for its CaseWise™ platform, a patient-informed resource...
Here’s our monthly update on all 35 portfolio stocks, including Cramer's favorite name to buy
This monthly portfolio review from the Investing Club represents a commentary update rather than a market-moving event. The piece...
J&J CEO says curing certain cancers within a decade is realistic
J&J CEO Joaquin Duato's statement on curing certain cancers within a decade signals the company's confidence in its oncology pipeline...
Johnson & Johnson CEO credits Trump tax policy for $55B US investment push, including $1B in Florida
Johnson & Johnson announced a $55 billion domestic investment program, with the CEO explicitly tying the decision to the Trump...
FHLC vs. IYH: Which Healthcare ETF Is the Better Buy in 2026?
This comparative analysis examines FHLC and IYH, two healthcare-focused exchange-traded funds, through the lens of portfolio composition...
Salesforce looks to strengthen its AI platform — plus, a positive note for J&J
Salesforce (CRM) is making a strategic push to enhance its AI capabilities within its platform ecosystem. This development signals the...
Jim Cramer Explains Johnson & Johnson’s (JNJ) Shares Have Gained
Johnson & Johnson (JNJ) has demonstrated substantial price appreciation, with shares climbing 53% over a 12-month period and posting 15%...
How to Build $3,000 a Month in Dividend Income Before You Turn 50
This article presents a personal finance strategy focused on constructing a dividend portfolio capable of generating $3,000 monthly...
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Legend Biotech (LEGN) announced Phase 1 clinical proof-of-concept for LB2501, an in vivo dual-targeting CAR-T therapy designed to...
New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma
Johnson & Johnson announced Phase 3 MonumenTAL-3 trial results for TALVEY® (talquetamab) combined with daratumumab in relapsed or...
Jim Cramer Says He Likes Drug Stocks Here As He Discusses Johnson & Johnson
Jim Cramer's public commentary on Johnson & Johnson (JNJ) represents a tactical sector rotation signal rather than a fundamental...
Jim Cramer Says He Likes Drug Stocks Here As He Discusses Johnson & Johnson
Prominent market commentator Jim Cramer expressed a constructive view on pharmaceutical equities, specifically highlighting Johnson &...
Is Johnson & Johnson (JNJ) A Good Stock To Buy Now?
Johnson & Johnson (JNJ) is the subject of renewed bullish commentary, with investment analysts highlighting potential upside for the...
SonoThera Raises $125M to Advance Gene Therapy
SonoThera's $125M Series B funding round represents incremental capital deployment in the competitive nonviral gene therapy space. While...
7 Best Longevity Stocks to Buy Now
The article highlights a thematic investment thesis centered on longevity stocks, reflecting growing institutional interest in companies...
RELATED TICKERS
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice